Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (78181)	3/20/2000 11:32:00 AM
From: BSGrinder	Read Replies (1) \| Respond to of 132070

Micheal, You are right, I'm not weeping about VASO, but I'm a little nervous about giving back 50% of price in one week. I've never had one of these "roman candle" stocks before. Thanks for the ride, /Kit

To: Knighty Tin who wrote (78181)	3/20/2000 5:27:00 PM
From: gnuman	Read Replies (1) \| Respond to of 132070

MB, This may be why vaso is down. GENERX is a non-surgically administered gene therapy designed to stimulate angiogenesis (new blood vessel growth), providing an alternate route for blood to flow around blocked or clogged arteries. Envisioned as an out-patient procedure that could be administered by cardiologists, GENERX involves a one-time, non-surgical administration of an adenoviral gene therapy vector containing the human Fibroblast Growth Factor-4 (FGF-4) angiogenic gene delivered into the coronary arteries through a standard catheter. Apparently provides the same type results as vaso treatments. biz.yahoo.com